Nanobiotix S.A. (NBTX)
| Market Cap | 1.61B |
| Revenue (ttm) | 38.27M |
| Net Income (ttm) | -28.13M |
| Shares Out | 48.39M |
| EPS (ttm) | -0.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 161,982 |
| Open | 33.66 |
| Previous Close | 33.11 |
| Day's Range | 32.34 - 33.91 |
| 52-Week Range | 3.15 - 41.89 |
| Beta | 0.55 |
| Analysts | Strong Buy |
| Price Target | 36.00 (+8.5%) |
| Earnings Date | Mar 31, 2026 |
About NBTX
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBT... [Read more]
Analyst Forecast
According to one analyst, the rating for NBTX stock is "Strong Buy" and the 12-month stock price target is $36.0.
News
Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery
(RTTNews) - Nanobiotix S.A.(NBTX), a late-stage clinical biotechnology company, announced on Monday preclinical data for the Nanoprimer platform in sequence with lipid nanoparticle-delivered recombina...
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver clearance P...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with...
Nanobiotix Earnings Call Transcript: H2 2025
Collaboration with J&J advanced NBTXR3 development in major oncology indications, while a strategic licensing amendment and non-dilutive financing improved financials, reducing net loss by 65% and extending cash runway into 2028. Key clinical data readouts are expected in 2026–2027.
Nanobiotix FY25 Net Loss Narrows; Expects Cash Runway Through Early 2028; Stock Down
(RTTNews) - Nanobiotix S.A. (NBTX), a late-clinical-stage biotechnology company, reported financial results for the year ended December 31, 2025, reflecting a narrower net loss and provided cash runwa...
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck can...
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
The stock's movement follows a statement clarifying that there is no ongoing process or assessment for a takeover, which has helped to stabilize investor sentiment as broader markets are experiencing ...
Nanobiotix (NBTX) Addresses Takeover Rumors
Nanobiotix (NBTX) Addresses Takeover Rumors
Nanobiotix Clarifies About Recent Media Speculations Regarding Potential Takeover, Stock Up
(RTTNews) - Nanobiotix S.A. (NBTX) issued a statement on Wednesday in response to recent media speculation concerning intentions for a potential public takeover.
NANOBIOTIX Statement Regarding Recent Media Speculation
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approa...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
NANOBIOTIX to Participate in Investor Conferences in March
PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News
Nanobiotix (NBTX) Sees Significant Price Target Increase by Guggenheim | NBTX Stock News
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based appro...
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
PARIS and CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based appro...
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Nanobiotix is a small French biotechnology company. It has secured financing from Johnson & Johnson and elsewhere.
Nanobiotix Transcript: Jefferies London Healthcare Conference 2025
A major partnership with J&J is advancing NBTXR3 through multiple late-stage trials in head and neck and lung cancers, targeting large, underserved markets. Early data show high response rates, and the company is expanding its nanophysics platforms for broader applications.
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
PARIS and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approa...
Nanobiotix Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Physics-based nanoparticles are being developed for broad solid tumor applications, with NBTXR3 leading in head and neck and lung cancer trials. J&J partnership drives global phase III and II studies, while $71M in financing extends runway to 2028.
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Royalty
Nanobiotix (NBTX) Secures $71M Financing Deal with HealthCare Royalty